한국에스지에스

비상장계속사업자

SGS Korea Co., Ltd.

피터 포세미어스

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

한국에스지에스

Business Reg. No. 1068159002 · CEO 피터 포세미어스

I.Investment Overview

Target한국에스지에스 (1068159002)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명한국에스지에스
영문명SGS Korea Co., Ltd.
대표자피터 포세미어스
사업자등록번호1068159002
법인등록번호1101110245757
설립일1979.02.02
종업원수1,095명

V.Workforce

1,095

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW1,785.420211,935.420222,042.820232,136.120242,321.22025
영업이익100M KRW191.12021166.1202215320232092024186.92025
순이익100M KRW117.92021129.12022132.82023180.72024149.82025
Item20252024202320222021
자산총계1,071.4억원952.7억원908.7억원867.7억원851.1억원
부채총계651.8억원502.1억원506.1억원468.8억원463.4억원
자본총계419.6억원450.5억원402.7억원398.9억원387.8억원
매출액2,321.2억원2,136.1억원2,042.8억원1,935.4억원1,785.4억원
영업이익186.9억원209억원153억원166.1억원191.1억원
순이익149.8억원180.7억원132.8억원129.1억원117.9억원

VII.Financial Ratios

FY2025 basis

8.05%

영업이익률

6.45%

순이익률

13.98%

ROA

35.69%

ROE

155.33%

부채비율

39.16%

자기자본비율

VIII.R&D Activity

Fields 농림수산식품 > 식품영양과학 · 농림수산식품 > 식품과학 · 보건의료 > 의료기기·S/W 안전관리

Keywords 의료기기, 분석품질관리, 가이드라인, 주요 영양성분, 주요 식품

YearProjectsPapersPatents
2025200
2024200
2023400
2022200
2021200
2020100
2019200
2018200
2017210
2016300
2015100
2013300
2012100
2011400
2010100

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

한국에스지에스 투심보고서 | Alpha Lenz